The Motley Fool··Sarah SidlowArdelyx CEO Sells $243K in Stock as Biotech Eyes Recovery
Ardelyx CEO sells $243K in shares via routine trading plan as company improves operationally; analysts see 170% upside potential.
ARDXclass action lawsuitbiotech